Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Genitourinary Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Genitourinary Other
    Genetic Alterations Associated With Cryptorchidism - (JAMA)
    Study Finds Association Between Cryptorchidism, Certain Genetic Mutations - (DGNews)
    Relationship Between Prostate Inflammation, Lower Urinary-Tract Symptoms Evident - (DGNews)
    CDC Releases First Estimate of HPV-Associated Cancer Data - (DGNews)
    Positive Urine Antigen Test Signifies More Severe Pneumonia: Presented at ICAAC/IDSA - (DGDispatch)

    News archive

     Recent webcasts/CME - Genitourinary Other
    • Reducing the Burden of Overactive Bladder: A Global Perspective
    • Overactive Bladder Is Highly Prevalent, Burdensome, and Costly
    • Guidelines Help Clinicians to Diagnose and Manage Patients With Overactive Bladder
    • Effective Options Available to Treat Overactive Bladder
    • The Treatment of Benign Prostatic Hyperplasia

      Webcasts/CME archive

       Recent cases - Genitourinary Other
        Penis Deformity after Intra-Urethral Liquid Paraffin Administration in a Young Male: A Case Report
        Inflammatory Myofibroblastic Tumor of Epididymis: A Case Report and Review of Literature
        Symplastic Scrotal Leiomyoma: A Case Report
        Testicular Seminoma Presenting with Duodenal Perforation: A Case Report
        Ureteral Fibroepithelial Polyps with Calculi: A Case Series

        Cases archive
          




        my personal edition > genitourinary other > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Testim (Testosterone Gel) Gel For Treatment Of Testosterone Deficiency In Men Now Available In US

        NORRISTOWN, PA -- February 4, 2003 -- Auxilium Pharmaceuticals, Inc. today announced the launch of Testim™, a patented testosterone gel. Auxilium received U.S. Food and Drug Administration (FDA) approval to market Testim on October 31, 2002, for use in treating men with low testosterone levels.

        Testim is a novel, topical gel formulation that is used to supplement low levels of testosterone in men with hypogonadism, a condition that occurs when a man's body does not produce adequate amounts of testosterone. Testosterone deficiency can lead to a decline in energy, decreased muscle mass, an increase in abdominal fat, reduced bone density leading to an increased risk of osteoporosis, decreased libido, decreased sexual function and impotence, anemia, fatigue, and depression.

        "In a randomized, cross-over study in hypogonadal men, Testim was shown to have 30 percent better testosterone absorption dose for dose than was seen with a commercial testosterone gel," said Thomas Marbury, M.D., associate professor, University of Florida and president, Orlando Clinical Research Center, principal investigator of this study.

        During the clinical trials of Testim, patients reported a 59 percent increase in sexual activity and a 78 percent increase in days with a spontaneous erection over a 90-day period. Patients also showed an average increase of 3.5 pounds in muscle mass in 90 days with no weight training and without overall weight gain. Initial analysis of long-term data suggests that Testim improves bone mineral density.

        "Testim gel is an improved, effective, easy to use new option for the treatment of hypogonadism for the millions of men across the country who suffer from the often life-altering effects of low testosterone levels," said Christopher P. Steidle, M.D., clinical associate professor of urology, Indiana University School of Medicine at Fort Wayne, one of the key investigators of the Testim development program. He continued, "the most exciting part of testosterone replacement therapy is the dramatic and positive feedback you hear from men after they've been on treatment. Testim helps men feel like themselves again."

        The Testim clinical trials were the largest ever conducted in testosterone replacement therapy, involving 690 hypogonadal men treated at 74 centers in the U.S. and Europe. Auxilium's worldwide development program for Testim also included the largest placebo-controlled testosterone replacement study ever conducted, with over 400 patients at 43 centers in the U.S.

        "With the many important advantages of Testim for patients, we believe there is a tremendous opportunity for its success in the marketplace," said Gerri Henwood, president and chief executive officer of Auxilium. "As more men become aware that it is possible to treat many of the debilitating symptoms associated with low testosterone we expect the demand for these treatments to increase and the market for testosterone replacement therapy to continue to grow, exceeding $2 billion by 2008."

        About four to five million American men suffer from hypogonadism and currently, only about 2 percent undergo treatment with testosterone replacement therapy. There are many causes of hypogonadism; including damage to the testes or pituitary gland from infection, trauma, radiation, or chemotherapy treatment, as well as congenital abnormalities such as Klinefelter Syndrome, a rare condition that occurs when a man is born with an extra X chromosome. The highest incidence of hypogonadism is seen in men over the age of 50. About 20 percent of men over the age of 50 experience hypogonadism and its many symptoms due to a decline in the production of testosterone.

        Testim is Auxilium's first commercial product and is being marketed in the United States by Auxilium and its professional sales force. Regulatory clearance for Testim was received only 22 months after initiation of the first clinical study. Testim utilizes a proprietary topical drug delivery technology licensed from Bentley Pharmaceuticals, Inc. (Amex: BNT).

        Auxilium Pharmaceuticals, Inc. was founded in 1999 to develop and market pharmaceutical products that improve health and restore function as we age. Auxilium has assembled a team of leading healthcare professionals and medical advisors with superior capabilities and decades of experience in pharmaceutical R&D and commercialization. The Company is seeking to expand its portfolio by licensing additional products for development or co-promotion. For additional information, visit http://www.auxilium.com .


        SOURCE: Auxilium Pharmaceuticals, Inc.



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send